Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H1 2018
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Pipeline Review, H1 2018
SUMMARY
According to the recently published report 'Poly [ADP Ribose] Polymerase 1 - Pipeline Review, H1 2018'; Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) pipeline Target constitutes close to 31 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes.
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Poly [ADP-ribose] polymerase 1 (PARP-1) is an enzyme encoded by the PARP1 gene.
It is involved in the base excision repair (BER) pathway, by catalyzing the poly (ADP-ribosylation) of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism.
It positively regulates the transcription of MTUS1 and negatively regulates the transcription of MTUS2/TIP150. It is required for PARP9 and DTX3L recruitment to DNA damage sites. PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites.
The report 'Poly [ADP Ribose] Polymerase 1 - Pipeline Review, H1 2018' outlays comprehensive information on the Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 5, 9, 1, 4 and 3 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Immunology, Respiratory, Toxicology and Undisclosed which include indications Ovarian Cancer, Breast Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Metastatic Breast Cancer, Small-Cell Lung Cancer, Solid Tumor, Gastric Cancer, Epithelial Ovarian Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Glioblastoma Multiforme (GBM), Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Cervical Cancer, Malignant Mesothelioma, Mantle Cell Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Transitional (Urothelial) Tract Cancer, Non-Hodgkin Lymphoma, Prostate Cancer, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), B-Cell Chronic Lymphocytic Leukemia, Bladder Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Essential Thrombocythemia, Ewing Sarcoma, Follicular Lymphoma, Germ Cell Tumors, Germinomatous (Seminomatous) Germ Cell Tumors, Glioma, Gynecological Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Laryngeal Cancer, Leiomyosarcoma, Lung Cancer, Lung Injury, Lung Transplant Rejection, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Prostate Cancer, Muscle Invasive Bladder Cancer (MIBC), Myelofibrosis, Neuroblastoma, Neuroendocrine Tumors, Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Organophosphate and Carbamate Poisoning, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Peritoneal Tumor, Polycythemia Vera, Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Soft Tissue Sarcoma, Squamous Non-Small Cell Lung Cancer, Testicular Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Traumatic Brain Injury, Unspecified and Uveal Melanoma.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Poly [ADP Ribose] Polymerase 1 - Pipeline Review, H1 2018'; Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) pipeline Target constitutes close to 31 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes.
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Poly [ADP-ribose] polymerase 1 (PARP-1) is an enzyme encoded by the PARP1 gene.
It is involved in the base excision repair (BER) pathway, by catalyzing the poly (ADP-ribosylation) of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism.
It positively regulates the transcription of MTUS1 and negatively regulates the transcription of MTUS2/TIP150. It is required for PARP9 and DTX3L recruitment to DNA damage sites. PARP1-dependent PARP9-DTX3L-mediated ubiquitination promotes the rapid and specific recruitment of 53BP1/TP53BP1, UIMC1/RAP80, and BRCA1 to DNA damage sites.
The report 'Poly [ADP Ribose] Polymerase 1 - Pipeline Review, H1 2018' outlays comprehensive information on the Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 5, 9, 1, 4 and 3 respectively.
Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Immunology, Respiratory, Toxicology and Undisclosed which include indications Ovarian Cancer, Breast Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Metastatic Breast Cancer, Small-Cell Lung Cancer, Solid Tumor, Gastric Cancer, Epithelial Ovarian Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Glioblastoma Multiforme (GBM), Metastatic Pancreatic Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Cervical Cancer, Malignant Mesothelioma, Mantle Cell Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Transitional (Urothelial) Tract Cancer, Non-Hodgkin Lymphoma, Prostate Cancer, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), B-Cell Chronic Lymphocytic Leukemia, Bladder Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Essential Thrombocythemia, Ewing Sarcoma, Follicular Lymphoma, Germ Cell Tumors, Germinomatous (Seminomatous) Germ Cell Tumors, Glioma, Gynecological Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Laryngeal Cancer, Leiomyosarcoma, Lung Cancer, Lung Injury, Lung Transplant Rejection, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Prostate Cancer, Muscle Invasive Bladder Cancer (MIBC), Myelofibrosis, Neuroblastoma, Neuroendocrine Tumors, Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Organophosphate and Carbamate Poisoning, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Parkinson's Disease, Peritoneal Tumor, Polycythemia Vera, Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Soft Tissue Sarcoma, Squamous Non-Small Cell Lung Cancer, Testicular Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Traumatic Brain Injury, Unspecified and Uveal Melanoma.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30)
- The report reviews Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics and enlists all their major and minor projects
- The report assesses Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Overview
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Companies Involved in Therapeutics Development
AbbVie Inc
American Gene Technologies International Inc
AstraZeneca Plc
BeiGene Ltd
Checkpoint Therapeutics Inc
Clovis Oncology Inc
Hager Biosciences LLC
Ildong Pharmaceutical Co Ltd
IMPACT Therapeutics Inc
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Mitsubishi Tanabe Pharma Corp
Nerviano Medical Sciences Srl
Shanghai Acebright Pharmaceuticals Group Co Ltd
Tasly Pharmaceutical Group Co Ltd
Tesaro Inc
Teva Pharmaceutical Industries Ltd
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Drug Profiles
2X-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABT-767 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-PD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-0108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-1775 + olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-6738 + olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cediranib maleate + olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CK-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDX-1197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMP-4297 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JPI-289 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-124 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
niraparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-118 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-293 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pamiparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-554 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rucaparib camsylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-10914 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-3162 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PARP-1 for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PARP1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target PARP1, 2, 3 and NO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOMCL-9112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tislelizumab + pamiparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TSL-1502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veliparib ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XZ-120312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YHP-743 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Dormant Products
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Discontinued Products
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Product Development Milestones
Featured News & Press Releases
Apr 06, 2018: Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer
Apr 03, 2018: The European Medicines Agency Accepts Regulatory Submission for Lynparza in BRCA-mutated HER2-Negative Metastatic Breast Cancer
Apr 02, 2018: Myriad Receives Pre-Market Approval for its BRACAnalysis Diagnostic System in Japan
Mar 26, 2018: Data from TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian Cancer
Mar 26, 2018: EMA Recommends Granting a Conditional Marketing Authorisation for Rucaparib
Mar 14, 2018: TESARO to Present Data on ZEJULA at AACR 2018 Annual Meeting
Mar 08, 2018: Clovis Oncology Announces Notice of Allowance for Rucaparib High Dosage Strength Tablet Patent with Expiration in 2035
Feb 27, 2018: TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results
Feb 23, 2018: Lynparza receives positive EU CHMP opinion in platinum-sensitive relapsed ovarian cancer
Feb 21, 2018: Clovis Oncology Receives Positive Trend Vote from CHMP in European Regulatory Review for Rucaparib Ovarian Cancer Treatment Indication
Feb 08, 2018: Once a day pill for ovarian cancer could be made available on the CDF
Feb 05, 2018: Newcastle University Provides Update on Anti-Neoplastic Agent Rucaparib
Jan 19, 2018: Lynparza receives approval in Japan for the treatment of advanced ovarian cancer
Jan 12, 2018: LYNPARZA (olaparib) Approved by US FDA in Germ line BRCA-mutated Metastatic Breast Cancer
Jan 03, 2018: Myriad Genetics Announces Expanded Research Collaboration with AstraZeneca
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Overview
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Companies Involved in Therapeutics Development
AbbVie Inc
American Gene Technologies International Inc
AstraZeneca Plc
BeiGene Ltd
Checkpoint Therapeutics Inc
Clovis Oncology Inc
Hager Biosciences LLC
Ildong Pharmaceutical Co Ltd
IMPACT Therapeutics Inc
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Mitsubishi Tanabe Pharma Corp
Nerviano Medical Sciences Srl
Shanghai Acebright Pharmaceuticals Group Co Ltd
Tasly Pharmaceutical Group Co Ltd
Tesaro Inc
Teva Pharmaceutical Industries Ltd
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Drug Profiles
2X-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABT-767 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-PD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-0108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-1775 + olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-6738 + olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cediranib maleate + olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CK-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IDX-1197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMP-4297 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JPI-289 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-124 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
niraparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-118 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-293 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pamiparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-554 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rucaparib camsylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-10914 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-3162 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PARP-1 for Unspecified Indication - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PARP1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Target PARP1, 2, 3 and NO for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOMCL-9112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tislelizumab + pamiparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TSL-1502 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
veliparib ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XZ-120312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YHP-743 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Dormant Products
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Discontinued Products
Poly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) - Product Development Milestones
Featured News & Press Releases
Apr 06, 2018: Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer
Apr 03, 2018: The European Medicines Agency Accepts Regulatory Submission for Lynparza in BRCA-mutated HER2-Negative Metastatic Breast Cancer
Apr 02, 2018: Myriad Receives Pre-Market Approval for its BRACAnalysis Diagnostic System in Japan
Mar 26, 2018: Data from TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian Cancer
Mar 26, 2018: EMA Recommends Granting a Conditional Marketing Authorisation for Rucaparib
Mar 14, 2018: TESARO to Present Data on ZEJULA at AACR 2018 Annual Meeting
Mar 08, 2018: Clovis Oncology Announces Notice of Allowance for Rucaparib High Dosage Strength Tablet Patent with Expiration in 2035
Feb 27, 2018: TESARO Announces Fourth-Quarter and Full-Year 2017 Operating Results
Feb 23, 2018: Lynparza receives positive EU CHMP opinion in platinum-sensitive relapsed ovarian cancer
Feb 21, 2018: Clovis Oncology Receives Positive Trend Vote from CHMP in European Regulatory Review for Rucaparib Ovarian Cancer Treatment Indication
Feb 08, 2018: Once a day pill for ovarian cancer could be made available on the CDF
Feb 05, 2018: Newcastle University Provides Update on Anti-Neoplastic Agent Rucaparib
Jan 19, 2018: Lynparza receives approval in Japan for the treatment of advanced ovarian cancer
Jan 12, 2018: LYNPARZA (olaparib) Approved by US FDA in Germ line BRCA-mutated Metastatic Breast Cancer
Jan 03, 2018: Myriad Genetics Announces Expanded Research Collaboration with AstraZeneca
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.2), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Products under Development by Companies, H1 2018 (Contd.4), H1 2018
Products under Development by Companies, H1 2018 (Contd.5), H1 2018
Products under Development by Companies, H1 2018 (Contd.6), H1 2018
Products under Development by Companies, H1 2018 (Contd.7), H1 2018
Products under Development by Companies, H1 2018 (Contd.8), H1 2018
Products under Development by Companies, H1 2018 (Contd.9), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AbbVie Inc, H1 2018
Pipeline by American Gene Technologies International Inc, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by BeiGene Ltd, H1 2018
Pipeline by Checkpoint Therapeutics Inc, H1 2018
Pipeline by Clovis Oncology Inc, H1 2018
Pipeline by Hager Biosciences LLC, H1 2018
Pipeline by Ildong Pharmaceutical Co Ltd, H1 2018
Pipeline by IMPACT Therapeutics Inc, H1 2018
Pipeline by Jeil Pharmaceutical Co Ltd, H1 2018
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018
Pipeline by Nerviano Medical Sciences Srl, H1 2018
Pipeline by Shanghai Acebright Pharmaceuticals Group Co Ltd, H1 2018
Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2018
Pipeline by Tesaro Inc, H1 2018
Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Discontinued Products, H1 2018
Discontinued Products, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.2), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Products under Development by Companies, H1 2018 (Contd.2), H1 2018
Products under Development by Companies, H1 2018 (Contd.3), H1 2018
Products under Development by Companies, H1 2018 (Contd.4), H1 2018
Products under Development by Companies, H1 2018 (Contd.5), H1 2018
Products under Development by Companies, H1 2018 (Contd.6), H1 2018
Products under Development by Companies, H1 2018 (Contd.7), H1 2018
Products under Development by Companies, H1 2018 (Contd.8), H1 2018
Products under Development by Companies, H1 2018 (Contd.9), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AbbVie Inc, H1 2018
Pipeline by American Gene Technologies International Inc, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by BeiGene Ltd, H1 2018
Pipeline by Checkpoint Therapeutics Inc, H1 2018
Pipeline by Clovis Oncology Inc, H1 2018
Pipeline by Hager Biosciences LLC, H1 2018
Pipeline by Ildong Pharmaceutical Co Ltd, H1 2018
Pipeline by IMPACT Therapeutics Inc, H1 2018
Pipeline by Jeil Pharmaceutical Co Ltd, H1 2018
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018
Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018
Pipeline by Nerviano Medical Sciences Srl, H1 2018
Pipeline by Shanghai Acebright Pharmaceuticals Group Co Ltd, H1 2018
Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2018
Pipeline by Tesaro Inc, H1 2018
Pipeline by Teva Pharmaceutical Industries Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Discontinued Products, H1 2018
Discontinued Products, H1 2018 (Contd.1), H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
AbbVie Inc
American Gene Technologies International Inc
AstraZeneca Plc
BeiGene Ltd
Checkpoint Therapeutics Inc
Clovis Oncology Inc
Hager Biosciences LLC
Ildong Pharmaceutical Co Ltd
IMPACT Therapeutics Inc
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Mitsubishi Tanabe Pharma Corp
Nerviano Medical Sciences Srl
Shanghai Acebright Pharmaceuticals Group Co Ltd
Tasly Pharmaceutical Group Co Ltd
Tesaro Inc
Teva Pharmaceutical Industries Ltd
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
AbbVie Inc
American Gene Technologies International Inc
AstraZeneca Plc
BeiGene Ltd
Checkpoint Therapeutics Inc
Clovis Oncology Inc
Hager Biosciences LLC
Ildong Pharmaceutical Co Ltd
IMPACT Therapeutics Inc
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Mitsubishi Tanabe Pharma Corp
Nerviano Medical Sciences Srl
Shanghai Acebright Pharmaceuticals Group Co Ltd
Tasly Pharmaceutical Group Co Ltd
Tesaro Inc
Teva Pharmaceutical Industries Ltd
